Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACYW135X meningococcal conjugate vaccine
- Development stage
- Phase 1
- Lead developer
- Beijing Kexing Zhongwei Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The ACYW135X meningococcal conjugate vaccine is a pentavalent vaccine candidate developed by Sinovac Life Sciences Co., Ltd. for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis*. It is designed to provide broader protection than existing quadrivalent (ACYW135) vaccines by including the serogroup X polysaccharide, which has been identified as an increasing threat in certain regions, particularly sub-Saharan Africa. The vaccine consists of capsular polysaccharides from serogroups A, C, Y, W135, and X, each individually conjugated to a carrier protein to enhance immunogenicity, particularly in young children, by inducing a T-cell dependent immune response. As of 2023, the vaccine is undergoing Phase 1 clinical evaluation to assess its safety and immunogenicity in healthy individuals aged 2 to 59 years.
- Other names
- Group ACYW135X meningococcal conjugate vaccinePentavalent meningococcal conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenX CPS (Neisseria meningitidis serogroup X capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on ACYW135X meningococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACYW135X meningococcal conjugate vaccine.